Navigation Links
NeurogesX Reports Second Quarter 2009 Results
Date:8/7/2009

10,139 19,274 ------ ------ Total liabilities and stockholders' equity $63,276 $25,590 ======= ======= (1) The balance sheet at December 31, 2008, has been derived from the audited consolidated financial statements at that date. NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Sara Pellegrino (investors) Chief Financial Officer (646) 536-7002 (650) 358-3310 spellegrino@theruthgroup.com Jason Rando (media) (646) 536-7025 jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
2. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
3. NeurogesX Added to Russell 3000 Index
4. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
5. NeurogesX to Present at Needham Life Sciences Conference
6. NeurogesX Receives European Commission Approval for Qutenza(TM)
7. NeurogesX Reports First Quarter 2009 Results
8. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
9. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
10. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
11. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... , , , , , , , ... , AUDIO: , A team of scientists from...y of Arizona, Cold Spring Harbor Laboratory and Io...A of corn. The... , , Click here ... , , , , , , , ...
(Date:11/20/2009)...nd Latin American countries have an opportunity to... Researchers from the University of Valencia (UV),...e studied the productive fabric of the Spanish bio...n,s food and plant sectors have more clout than th...gy as applied to food and plants has been overlook...
(Date:11/20/2009)..., SAN DIEGO, Nov. 20 Veridiam (www...n the mid-size company category at the 2009 Workpl... the San Diego Society for Human Resources Managem... resources practices. ,, Veridiam was one of ni...ominated companies, honored at the recent awards c...
(Date:11/20/2009)..., SEATTLE, Nov. 20 Dend...that the U.S. Food and Drug Administration (FDA) p... amended Biologics License Application (BLA) for P...e. The FDA has assigned a Prescription Drug User ... it will respond to Dendreon,s amended BLA. Dendr...
Breaking Biology Technology:Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Spanish biotechnology should focus on food and plant sectors to be more competitive 2Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3
... World,Heart Corporation ("WorldHeart") today anno...Agreement dated June 20, 2008 among WorldHeart, it..."), Abiomed, Inc.,("Abiomed"), Venrock Partners V,...epreneurs Fund V, L.P. (collectively, "Venrock"), ...ons Cayman Fund, L.P., Special,Situations Private ...
...asdaq: ATSI ), manufacturer and marketer of state... today announced Health Canada -- Medical,Device B... use of the ATS,Open Pivot(R) AP360(TM) Mechanical...-bin/prnh/20040202/ATSILOGO ), The ATS AP360 hea...new,supra-annular cuff design that facilitates imp...
...tion,(NYSE: SYK ) announced that it will host a c...p.m., Eastern Time, to discuss the Company,s opera...nd provide an operational,update. Operating result...ased at 4:00 p.m. that day., Stephen P. MacMillan...ergy, Vice President and Chief Financial Officer, ...
Other Biology Technology:WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 2WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 3WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 4WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 5WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 6ATS Medical Announces Canadian Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve 2Stryker To Host Conference Call On July 17, 2008 2
(Date:11/21/2009)...c newswire / - KINAXO Biotechnologies GmbH annou...two new investors in the company, Leifina and Conm...gen Schumacher has been elected as a new member of...ers Axel Ullrich, Hellmut Kirchner, Manfred Ferber...ountain Partners, BioM, High-Tech Grnderfonds, the...
(Date:11/20/2009)...entific and technological frontiers. The National ...hat totals nearly $4.3 million for the diverse eff...ican Recovery and Reinvestment Act of 2009. , ...stigation of solar phenomena. Philip R. Goode, dis...capabilities of NJIT,s Big Bear Solar Observatory ...
(Date:11/20/2009)...mber 2009 issue of the journal GENETICS ( http:/...of genes (1-aminocyclopropane-1-carboxylate syntha...f ethylene. This gas affects many aspects of plant...tion for future genetic manipulation that could ma...hrive in difficult terrain, increase yields, and o...
Breaking Biology News(10 mins):KINAXO Completes Financing Round to Enhance Biomarker Development 2KINAXO Completes Financing Round to Enhance Biomarker Development 3NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2It's a gas: New discovery may lead to heartier, high-yielding plants 2Top Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution 53191 1Top Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution 53191 2Top Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution 53191 3Top Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution 53191 4Eli Lilly 26 Company and ScinoPharm Taiwan Ltd Announce Settlement of Gemcitabine Litigation 13272 1Eli Lilly 26 Company and ScinoPharm Taiwan Ltd Announce Settlement of Gemcitabine Litigation 13272 2Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 1Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 2Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 3Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 4Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 5Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 6Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 7Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 8Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 9Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 10Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 11Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 12Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 13Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 14Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 15Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 16Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 17Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 18Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 19Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 20Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 21Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 22Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 23Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 24Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 25Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 26Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 27Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 28Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 29
...both UCLA and a team of enterprising UCLA scientis...ch and patient care. , In 1996, a unique collab... Belldegrun founded the biotechnology company Agen...million through an acquisition by Astellas Pharma ...ed private biotech firms poised to tackle therapeu...
...of Texas at Austin has received $1.9 million to ex...e national decisions about placement of devices to...partment of Homeland Security provided the funds t...ect smuggling in Russia and other countries of the...ty for their stores of nuclear weapons material an...
.... A ten-week expedition to the Lazarev Sea and the... Antarctic research season of the German research ...just some two hours after an official ceremony at ...arstern,s 25th anniversary of service, the researc...the Southern Ocean from Cape Town. The 53 scientis...
Other Biology News:Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 2Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 3Improving detection of nuclear smuggling goal of computer model of mechanical engineer 2Improving detection of nuclear smuggling goal of computer model of mechanical engineer 3Climate change and life in the Southern Ocean 2Climate change and life in the Southern Ocean 3Climate change and life in the Southern Ocean 4
Mouse Anti-Human S-100 alpha/beta chain Monoclonal Antibody, Unconjugated, Clone 8B10 from Santa Cruz Biotechnology, Inc.
Baker's yeast (S. cerevisiae) Phosphoglucose isomerase from Sigma-Aldrich
S-Protein Agarose from Novagen
ATX Ponceau S red staining solution from Sigma-Aldrich
Biology Products: